1-6 of 6
Susan J. McCall
Close
Sort by
Journal Articles

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL

Clinical Trials & Observations Brief Report
Craig S. Sauter, Matthew J. Matasar, Heiko Schoder, Sean M. Devlin, Pamela Drullinsky, John Gerecitano, Anita Kumar, Ariela Noy, Maria L. Palomba, Carol S. Portlock, David J. Straus, Andrew D. Zelenetz, Susan J. McCall, Shoshana T. Miller, Amanda I. Courtien, Anas Younes, Craig H. Moskowitz
Journal: Blood
Blood (2018) 131 (16): 1805–1808.
https://doi.org/10.1182/blood-2017-08-802561
Published: 2018
Includes: Supplemental data
Journal Articles

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

Clinical Trials & Observations
Alison J. Moskowitz, Heiko Schöder, Somali Gavane, Katie L. Thoren, Martin Fleisher, Joachim Yahalom, Susan J. McCall, Briana R. Cadzin, Stephanie Y. Fox, John Gerecitano, Ravinder Grewal, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew Matasar, Andy Ni, Ariela Noy, M. Lia Palomba, Miguel-Angel Perales, Carol S. Portlock, Craig Sauter, David Straus, Anas Younes, Andrew D. Zelenetz, Craig H. Moskowitz
Journal: Blood
Blood (2017) 130 (20): 2196–2203.
https://doi.org/10.1182/blood-2017-06-788877
Published: 2017
Journal Articles

Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588

Craig S. Sauter, MD, Stephanie L. Verwys, Susan J. McCall, MSN ANP-BC, Shoshana T. Miller, Amanda I. Courtien, Heiko Schoder, MD, Pamela Harris, MD, Matthew J. Matasar, MD MS, Anas Younes, MD, Craig H. Moskowitz, MD
Journal: Blood
Blood (2016) 128 (22): 4198.
https://doi.org/10.1182/blood.V128.22.4198.4198
Published: 2016
Journal Articles

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Clinical Trials & Observations
Anita Kumar, Carla Casulo, Joachim Yahalom, Heiko Schöder, Paul M. Barr, Philip Caron, April Chiu, Louis S. Constine, Pamela Drullinsky, Jonathan W. Friedberg, John F. Gerecitano, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Alexandra G. Jacob, Matthew J. Matasar, Gianna N. McArthur, Susan J. McCall, Alison J. Moskowitz, Ariela Noy, Maria L. Palomba, Carol S. Portlock, David J. Straus, Nicholas VanderEls, Stephanie L. Verwys, Joanna Yang, Anas Younes, Andrew D. Zelenetz, Zhigang Zhang, Craig H. Moskowitz
Journal: Blood
Blood (2016) 128 (11): 1458–1464.
https://doi.org/10.1182/blood-2016-03-703470
Published: 2016
Includes: Supplemental data
Journal Articles

Risk Factors Predicting Outcomes for Primary Refractory Hodgkin Lymphoma Patients Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation

Gunjan L Shah, MDMS, Kurt S Bantilan, MPH, Stephanie L Verwys, BS, Susan J McCall, MSN ANP-BC, Joachim Yahalom, MD, Matthew J. Matasar, MD MS, Alison J Moskowitz, MD, Craig H. Moskowitz, MD
Journal: Blood
Blood (2015) 126 (23): 520.
https://doi.org/10.1182/blood.V126.23.520.520
Published: 2015
Journal Articles

TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin

Alison J Moskowitz, MD, Sun Cho, Martin Fleisher, PhD, Kaitlin M Woo, MS, Zhigang Zhang, PhD, Stephanie Fox, Susan J McCall, MSN ANP-BC, Heiko Schoder, MD, Joachim Yahalom, MD, Craig H Moskowitz, MD
Journal: Blood
Blood (2015) 126 (23): 180.
https://doi.org/10.1182/blood.V126.23.180.180
Published: 2015